Check out the companies making the biggest moves premarket: Roivant Sciences — Shares rallied 24% after the pharma company said Phase 2 trial results for subsidiary Pulmovant’s mosliciguat demonstrated “a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance” in patients with pulmonary hypertension with interstitial lung disease. Lockheed Martin — The defense contractor ticked 0.7% higher after UBS upgraded the stock to buy from neutral, citing underappreciated earnings growth potential . Novartis — The drugmaker tumbled 12% after Phase 3 results showed its del-desiran drug led to no “significant improvement” in patients with myotonic dystrophy type 1. Peloton Interactive — Shares slid more than 4% after a Morgan Stanley downgrade to underweight from equal weight. “PTON is facing structural headwinds in fitness,” Morgan Stanley said. Boston Scientific — The medical device maker slipped more than 2% after the company said a recent cyberattack likely impacted sales and profit targets for 2026.
